LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Search

BioCryst Pharmaceuticals Inc

Fermé

SecteurSoins de santé

7.62 -0.13

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.55

Max

7.62

Chiffres clés

By Trading Economics

Revenu

5.1M

5.1M

Ventes

18M

163M

Marge bénéficiaire

3.113

Employés

580

EBITDA

7.2M

28M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+129.36% upside

Dividendes

By Dow Jones

Prochains Résultats

3 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-172M

1.7B

Ouverture précédente

7.75

Clôture précédente

7.62

Sentiment de l'Actualité

By Acuity

50%

50%

132 / 371 Classement par Healthcare

BioCryst Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 sept. 2025, 18:25 UTC

Principaux Mouvements du Marché

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27 sept. 2025, 07:00 UTC

Résultats

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27 sept. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 sept. 2025, 21:56 UTC

Acquisitions, Fusions, Rachats

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 sept. 2025, 20:54 UTC

Résultats

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 sept. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 sept. 2025, 20:27 UTC

Acquisitions, Fusions, Rachats

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 sept. 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 sept. 2025, 19:53 UTC

Acquisitions, Fusions, Rachats

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept. 2025, 19:40 UTC

Résultats

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 sept. 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 sept. 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 sept. 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 sept. 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26 sept. 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 sept. 2025, 18:50 UTC

Market Talk
Résultats

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 sept. 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26 sept. 2025, 18:02 UTC

Acquisitions, Fusions, Rachats

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 sept. 2025, 18:02 UTC

Acquisitions, Fusions, Rachats

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 sept. 2025, 18:02 UTC

Acquisitions, Fusions, Rachats

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 sept. 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 sept. 2025, 16:56 UTC

Market Talk
Résultats

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 sept. 2025, 16:41 UTC

Market Talk
Résultats

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 sept. 2025, 16:26 UTC

Résultats

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 sept. 2025, 16:12 UTC

Market Talk

Nike Stock Seen With Limited Upside -- Market Talk

26 sept. 2025, 15:59 UTC

Market Talk

Global Equities Roundup: Market Talk

26 sept. 2025, 15:59 UTC

Market Talk

Nike Seen Showing Progress in Turnaround -- Market Talk

Comparaison

Variation de prix

BioCryst Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

129.36% hausse

Prévisions sur 12 Mois

Moyen 17.5 USD  129.36%

Haut 30 USD

Bas 12 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

6

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

132 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
help-icon Live chat